Zhu Chen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10875521/publications.pdf

Version: 2024-02-01

97 papers	10,354 citations	101384 36 h-index	48187 88 g-index
97 all docs	97 docs citations	97 times ranked	13781 citing authors

#	Article	IF	Citations
1	PLCG1 is required for AML1-ETO leukemia stem cell self-renewal. Blood, 2022, 139, 1080-1097.	0.6	16
2	Transcriptome-wide subtyping of pediatric and adult T cell acute lymphoblastic leukemia in an international study of 707 cases. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2120787119.	3.3	18
3	Yolk sac-derived Pdcd11-positive cells modulate zebrafish microglia differentiation through the NF-Î²B-Tgfî²1 pathway. Cell Death and Differentiation, 2021, 28, 170-183.	5.0	9
4	A novel KMT2Aâ€“USO1 fusion geneâ€induced de novo secondary acute myeloid leukaemia in a patient initially diagnosed with acute promyelocytic leukaemia. British Journal of Haematology, 2021, 192, e32-e36.	1.2	2
5	Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial). Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	31
6	Activated factor X targeted stored in platelets as an effective gene therapy strategy for both hemophilia A and B. Clinical and Translational Medicine, 2021, 11, e375.	1.7	4
7	Integration of Genomic and Transcriptomic Markers Improves the Prognosis Prediction of Acute Promyelocytic Leukemia. Clinical Cancer Research, 2021, 27, 3683-3694.	3.2	16
8	DNA crosslinking and recombinationâ€activating genes 1/2 (RAG1/2) are required for oncogenic splicing in acute lymphoblastic leukemia. Cancer Communications, 2021, 41, 1116-1136.	3.7	7
9	Inherent hepatocytic heterogeneity determines expression and retention of edited F9 alleles post-AAV/CRISPR infusion. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, e2110887118.	3.3	1
10	Interferon regulatory factor 2 binding protein 2b regulates neutrophil versus macrophage fate during zebrafish definitive myelopoiesis. Haematologica, 2020, 105, 325-337.	1.7	9
11	Reply to Kesici et al. and Zeng et al.: Blocking the virus and reducing the inflammatory damage in COVID-19. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 12529-12530.	3.3	30
12	SETD2 deficiency accelerates MDS-associated leukemogenesis via S100a9 in NHD13 mice and predicts poor prognosis in MDS. Blood, 2020, 135, 2271-2285.	0.6	31
13	Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 9490-9496.	3.3	1,601
14	An allosteric PGAM1 inhibitor effectively suppresses pancreatic ductal adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 23264-23273.	3.3	27
15	MLL is required for miRNA-mediated translational repression. Cell Discovery, 2019, 5, 43.	3.1	3
16	Treating leukemia: differentiation therapy for mIDH2 AML. Cell Research, 2019, 29, 427-428.	5.7	1
17	International Collaboration to Save Children With Acute Lymphoblastic Leukemia. Journal of Global Oncology, 2019, 5, 1-2.	0.5	9
18	TAMM41 is required for heart valve differentiation via regulation of PINK-PARK2 dependent mitophagy. Cell Death and Differentiation, 2019, 26, 2430-2446.	5.0	22

#	Article	IF	Citations
19	Destabilization of AETFC through C/EBPÎ±-mediated repression of LYL1 contributes to t(8;21) leukemic cell differentiation. Leukemia, 2019, 33, 1822-1827.	3.3	5
20	Different roles of E proteins in t(8;21) leukemia: E2-2 compromises the function of AETFC and negatively regulates leukemogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 890-899.	3.3	18
21	Anticancer activity of green synthesised AgNPs from Cymbopogon citratus (LG) against lung carcinoma cell line A549. IET Nanobiotechnology, 2019, 13, 178-182.	1.9	9
22	Updated Phase 1 Results of a First-in-Human Open-Label Study of Lcar-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (Bcma). Blood, 2019, 134, 1858-1858.	0.6	15
23	Differential Expression of CD49f Discriminates the Independently Emerged Hematopoietic Stem Cells and Erythroid-Biased Progenitors. Blood, 2019, 134, 3700-3700.	0.6	3
24	Dynamic Analysis of Cytokine Profile for Cytokine Release Syndrome in Multiple Myeloma Patients after CAR-T Cell Therapy. Blood, 2019, 134, 5617-5617.	0.6	2
25	Identification of fusion genes and characterization of transcriptome features in T-cell acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 373-378.	3.3	104
26	Structural basis of DUX4/IGH-driven transactivation. Leukemia, 2018, 32, 1466-1476.	3.3	21
27	Setd2 deficiency impairs hematopoietic stem cell self-renewal and causes malignant transformation. Cell Research, 2018, 28, 476-490.	5.7	43
28	Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E11711-E11720.	3.3	192
29	Profiling and functional analysis of circular RNAs in acute promyelocytic leukemia and their dynamic regulation during all-trans retinoic acid treatment. Cell Death and Disease, 2018, 9, 651.	2.7	52
30	TanCAR T cells targeting CD19 and CD133 efficiently eliminate MLL leukemic cells. Leukemia, 2018, 32, 2012-2016.	3.3	37
31	RNF4 regulates zebrafish granulopoiesis through the DNMT1â€C/EBPÎ± axis. FASEB Journal, 2018, 32, 4930-4940.	0.2	5
32	Angiogenesis Induced By Aminoacyl-tRNA Synthetase Deficiency Is Dependent on Amino Acid Response (AAR) but Not Unfolded Protein Response (UPR) Pathways. Blood, 2018, 132, 77-77.	0.6	1
33	Conditional knockin of Dnmt3a R878H initiates acute myeloid leukemia with mTOR pathway involvement. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 5237-5242.	3.3	54
34	Caspase-3 controls AML1-ETOâ€“driven leukemogenesis via autophagy modulation in a ULK1-dependent manner. Blood, 2017, 129, 2782-2792.	0.6	39
35	GATA5 SUMOylation is indispensable for zebrafish cardiac development. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 1691-1701.	1.1	13
36	Palladin is a novel microtubule-associated protein responsible for spindle orientation. Scientific Reports, 2017, 7, 11806.	1.6	1

#	Article	IF	Citations
37	Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure. Cancer Cell, 2017, 32, 552-560.	7.7	219
38	Genomic Profiling of Adult and Pediatric B-cell Acute Lymphoblastic Leukemia. EBioMedicine, 2016, 8, 173-183.	2.7	241
39	Genome-wide studies identify a novel interplay between AML1 and AML1/ETO in t(8;21) acute myeloid leukemia. Blood, 2016, 127, 233-242.	0.6	44
40	The 12-year follow-up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia. Blood, 2016, 128, 1525-1528.	0.6	59
41	Allâ€trans retinoic acid and arsenic combination therapy benefits lowâ€toâ€intermediateâ€risk patients with newly diagnosed acute promyelocytic leukaemia: a longâ€term followâ€up based on multivariate analysis. British Journal of Haematology, 2015, 171, 277-280.	1.2	12
42	CCAAT/enhancer-binding protein Î± is required for hepatic outgrowth via the p53 pathway in zebrafish. Scientific Reports, 2015, 5, 15838.	1.6	11
43	Valproic Acid Ameliorates Graft-versus-Host Disease by Downregulating Th1 and Th17 Cells. Journal of Immunology, 2015, 195, 1849-1857.	0.4	23
44	DNA methyltransferase 1 functions through C/ebpa to maintain hematopoietic stem and progenitor cells in zebrafish. Journal of Hematology and Oncology, 2015, 8, 15.	6.9	40
45	Vibsanin B Preferentially Targets HSP90Î², Inhibits Interstitial Leukocyte Migration, and Ameliorates Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2015, 194, 4489-4497.	0.4	23
46	Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide. EBioMedicine, 2015, 2, 563-571.	2.7	42
47	Sumoylation of CCAAT/enhancer-binding protein Î± is implicated in hematopoietic stem/progenitor cell development through regulating runx1 in zebrafish. Scientific Reports, 2015, 5, 9011.	1.6	16
48	Systematic identification of arsenic-binding proteins reveals that hexokinase-2 is inhibited by arsenic. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15084-15089.	3.3	126
49	The DNA Binding Property of PML/RARA but Not the Integrity of PML Nuclear Bodies Is Indispensable for Leukemic Transformation. PLoS ONE, 2014, 9, e104906.	1.1	3
50	H3K36 Histone Methyltransferase Setd2 Is Required for Murine Embryonic Stem Cell Differentiation toward Endoderm. Cell Reports, 2014, 8, 1989-2002.	2.9	67
51	Challenges to effective cancer control in China, India, and Russia. Lancet Oncology, The, 2014, 15, 489-538.	5.1	411
52	Progress in the treatment of acute promyelocytic leukemia: optimization and obstruction. International Journal of Hematology, 2014, 100, 38-50.	0.7	17
53	Genomic landscape of CD34 ⁺ hematopoietic cells in myelodysplastic syndrome and gene mutation profiles as prognostic markers. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 8589-8594.	3.3	52
54	Curing APL through PML/RARA degradation by As2O3. Trends in Molecular Medicine, 2012, 18, 36-42.	3.5	126

#	Article	IF	Citations
55	Arsenic compounds: revived ancient remedies in the fight against human malignancies. Current Opinion in Chemical Biology, 2012, 16, 92-98.	2.8	66
56	From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood, 2011, 117, 6425-6437.	0.6	170
57	Translational medicine should translate medical science and technology into health care for everyone in China. Science China Life Sciences, 2011, 54, 1074-1076.	2.3	7
58	Using sound Clinical Paths and Diagnosis-related Groups (DRGs)-based payment reform to bring benefits to patient care: A case study of leukemia therapy. Frontiers of Medicine in China, 2010, 4, 8-15.	0.1	8
59	Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nature Reviews Cancer, 2010, 10, 775-783.	12.8	420
60	Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 3342-3347.	3.3	380
61	Fast Cocyclic Jacket Transform. IEEE Transactions on Signal Processing, 2008, 56, 2143-2148.	3.2	31
62	Acute promyelocytic leukemia: from highly fatal to highly curable. Blood, 2008, 111, 2505-2515.	0.6	1,107
63	A Simple Cocyclic Jacket Matrices. Mathematical Problems in Engineering, 2008, 2008, 1-18.	0.6	1
64	Front-Line Therapy with Arsenic Trioxide/All-Trans-Retinoic Acid Combination and Chemotherapy Improves Cure Rates in Newly Diagnosed Patients with Acute Promyelocytic Leukemia. Blood, 2008, 112, 2970-2970.	0.6	0
65	Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Philosophical Transactions of the Royal Society B: Biological Sciences, 2007, 362, 959-971.	1.8	126
66	Mutant Transcription Factors and Tyrosine Kinases as Therapeutic Targets for Leukemias: From Acute Promyelocytic Leukemia to Chronic Myeloid Leukemia and Beyond. Advances in Cancer Research, 2007, 98, 191-220.	1.9	6
67	From dissection of disease pathogenesis to elucidation of mechanisms of targeted therapies: leukemia research in the genomic era. Acta Pharmacologica Sinica, 2007, 28, 1434-1449.	2.8	9
68	The RARa-PLZF Oncogenic Protein Inhibits C/EBPa Function in Myeloid Cells.. Blood, 2007, 110, 1825-1825.	0.6	0
69	Gain-of-Function Mutations of GATA-2 in Acute Myeloid Transformation of Chronic Myeloid Leukemia.. Blood, 2007, 110, 1022-1022.	0.6	9
70	Aberrant Transcriptional Regulation of the MLL Fusion Partner EEN Gene by AML1-ETO and Its Implication in Leukemogenesis.. Blood, 2006, 108, 4330-4330.	0.6	0
71	Acute promyelocytic leukemia: A model of molecular target based therapy. Hematology, 2005, 10, 270-280.	0.7	19
72	Arsenic in cancer therapy. Anti-Cancer Drugs, 2005, 16, 119-127.	0.7	65

#	Article	IF	Citations
73	How patients have benefited from mouse models of acute promyelocytic leukaemia. Nature Reviews Cancer, 2005, 5, 821-827.	12.8	36
74	Retinoic Acid and Arsenic for Treating Acute Promyelocytic Leukemia. PLoS Medicine, 2005, 2, e12.	3.9	45
75	Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 7653-7658.	3.3	240
76	Molecular Characterization of NRG Gene, a Novel Partner, Fused to NUP98 Gene as a Result of the t(3;11)(q29q13;p15) Translocation in an Acute Myeloid/T Lymphocytic Leukemia.. Blood, 2005, 106, 4335-4335.	0.6	0
77	Arsenic Trioxide and Leukemia. , 2005, , 251-272.		0
78	All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 5328-5335.	3.3	564
79	Treatment of Acute Promyelocytic Leukemia with ATRA and As₂O₃: A Model of Molecular. Cancer Biology and Therapy, 2002, 1, 614-620.	1.5	73
80	Expanding the use of arsenic trioxide: Leukemias and beyond. Seminars in Hematology, 2002, 39, 22-26.	1.8	74
81	Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk. Blood, 2002, 99, 1014-1022.	0.6	84
82	How acute promyelocytic leukaemia revived arsenic. Nature Reviews Cancer, 2002, 2, 705-714.	12.8	309
83	Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk. Blood, 2002, 99, 1014-22.	0.6	26
84	Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood, 2001, 97, 264-269.	0.6	210
85	Association of the R485K polymorphism of the Factor V gene with poor response to activated protein C and increased risk of coronary artery disease in the Chinese population. Clinical Genetics, 2001, 57, 296-303.	1.0	30
86	Feasibility and clinical significance of real-time quantitative RTâ€“PCR assay of PML-RARÎ± fusion transcript in patients with acute promyelocytic leukemia. The Hematology Journal, 2001, 2, 330-340.	2.0	13
87	The localization of type 2 diabetes susceptibility gene loci in northern Chinese Han families. Science Bulletin, 2000, 45, 1792-1795.	1.7	0
88	Studies on Treatment of Acute Promyelocytic Leukemia With Arsenic Trioxide: Remission Induction, Follow-Up, and Molecular Monitoring in 11 Newly Diagnosed and 47 Relapsed Acute Promyelocytic Leukemia Patients. Blood, 1999, 94, 3315-3324.	0.6	579
89	Cellular and molecular mechanism of arsenic trioxide in the treatment of hematopoietic malignancies. , 1999, 5, 82-88.		0
90	Application of radiation hybrid in gene mapping. Science in China Series C: Life Sciences, 1998, 41, 644-649.	1.3	1

#	Article	IF	Citations
91	Combined Arsenic and Retinoic Acid Treatment Enhances Differentiation and Apoptosis in Arsenic-Resistant NB4 Cells. Blood, 1998, 91, 4300-4310.	0.6	176
92	Use of Arsenic Trioxide (As2O3) in the Treatment of Acute Promyelocytic Leukemia (APL): II. Clinical Efficacy and Pharmacokinetics in Relapsed Patients. Blood, 1997, 89, 3354-3360.	0.6	1,316
93	Retinoic acid regulatory pathways, chromosomal translocations, and acute promyelocytic leukemia. , 1996, 15, 147-156.		48
94	Acute promyelocytic leukemia: From clinic to molecular biology. Stem Cells, 1995, 13, 22-31.	1.4	43
95	Breakpoint clusters of thePML gene in acute promyelocytic leukemia: Primary structure of the reciprocal products of thePML-RARA gene in a patient with t(15;17). Genes Chromosomes and Cancer, 1993, 6, 133-139.	1.5	54
96	RARA and PML Genes in Acute Promyelocytic Leukemia. Leukemia and Lymphoma, 1992, 8, 253-260.	0.6	26
97	Retinoic Acid and Arsenic Trioxide Treatment in Acute Promyelocytic Leukemia: A Model of Oncoprotein Targeted Therapy. , 0, , 371-392.		0